Cargando…

Long-Term Response and Possible Cure of Patients With B-Cell Malignancies With Dose-Escalated Rituximab

Rituximab (R), a chimeric monoclonal antibody targeting CD20 antigen on B-cells, has become a standard of care in the treatment of B-cell malignancies, most often in conjunction with cytotoxic chemotherapy. Activity has been demonstrated in many subtypes of B-cell lymphoma, including diffuse large c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jacobs, Lauren M., Wiernik, Peter H., Dutcher, Janice P., Muxi, Pablo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5298442/ https://www.ncbi.nlm.nih.gov/pubmed/28203581 http://dx.doi.org/10.1177/2324709617691307

Ejemplares similares

Biologic response modifiers in gynecologic malignancies.
por: Dutcher, J. P., et al.
Publicado: (1988)

Pure Red Cell Aplasia Following Interleukin-2 Therapy
por: Dutcher, Janice P., et al.
Publicado: (2016)

Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2
por: Clark, Joseph I, et al.
Publicado: (2021)

Long-Term Outcomes of Dose-Escalated Hypofractionated Radiotherapy in Localized Prostate Cancer
por: Lazo, Antonio, et al.
Publicado: (2022)

Long-term tolerance and outcomes for dose escalation in early salvage post-prostatectomy radiation therapy
por: Safdieh, Joseph J., et al.
Publicado: (2014)

A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas
por: Nghiemphu, Phioanh Leia, et al.
Publicado: (2012)

Sex differences in high opioid dose escalation among Malaysian patients with long term opioid therapy
por: Zin, Che Suraya, et al.
Publicado: (2019)

Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study
por: Egle, Alexander, et al.
Publicado: (2018)

Management of hepatitis B in the era of checkpoint inhibition
por: Dutcher, Janice
Publicado: (2020)

Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up
por: Creak, A, et al.
Publicado: (2013)

Effective treatment of CLIPPERS with long-term use of rituximab
por: Cipriani, Veronica P., et al.
Publicado: (2018)

Long-term persistence with rituximab in patients with rheumatoid arthritis
por: Oldroyd, Alexander G S, et al.
Publicado: (2018)

Infusion Rate Escalation Study of Rituximab in Patients with CD20+ B-Cell Lymphomas: A Single Institution Analysis in Japan
por: Yokoyama, Masahiro, et al.
Publicado: (2013)

Phase Ib dose-escalation study of the selective, noncovalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies
por: Allan, John N., et al.
Publicado: (2021)

T-cell response to 3 doses of Sars-Cov2 BNT162b2 Pfizer vaccine in long term rituximab treated patients
por: Heitz, Jade, et al.
Publicado: (2022)

Percutaneous Parametrial Dose Escalation in Women with Advanced Cervical Cancer: Feasibility and Efficacy in Relation To Long-term Quality of Life
por: Akbaba, Sati, et al.
Publicado: (2018)

Long-term outcomes of rituximab, temozolomide and high-dose methotrexate without consolidation therapy for lymphoma involving the CNS
por: Nagle, Sarah J, et al.
Publicado: (2017)

Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies
por: Brada, M, et al.
Publicado: (1999)

Sorafenib Dose Escalation is Not Uniformly Associated with Blood Pressure Elevations in Normotensive Patients with Advanced Malignancies
por: Karovic, Sanja, et al.
Publicado: (2014)

Phase I, multicenter, dose‐escalation study of avadomide in adult Japanese patients with advanced malignancies
por: Hatake, Kiyohiko, et al.
Publicado: (2020)

Dose escalation of a curcuminoid formulation
por: Lao, Christopher D, et al.
Publicado: (2006)

Metastatic Sigmoid Colon Malignancy With a Synchronous Carcinoma Breast: Is Cure Possible?
por: Gadiyaram, Srikanth, et al.
Publicado: (2022)

Dose Escalation of Oropharyngeal Cancer: Long-Time Follow-Up and Side Effects
por: Embring, Anna, et al.
Publicado: (2023)

Maximum Tolerated Dose and Pharmacokinetics of Paclitaxel Micellar in Patients with Recurrent Malignant Solid Tumours: A Dose-Escalation Study
por: Borgå, Olof, et al.
Publicado: (2019)

Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases
por: Memon, Anza B., et al.
Publicado: (2018)

Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis
por: Hainsworth, John D
Publicado: (2003)

Long‐Term Safety of Rituximab in Granulomatosis With Polyangiitis and in Microscopic Polyangiitis
por: Merkel, Peter A., et al.
Publicado: (2021)

Long-Term Safety of Rituximab (Risks of Viral and Opportunistic Infections)
por: Varley, Cara D., et al.
Publicado: (2021)

Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
por: Wheeler, Graham M.
Publicado: (2016)

Clinical use of rituximab in haematological malignancies
por: Avivi, I, et al.
Publicado: (2003)

Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open
por: Sands, Bruce E., et al.
Publicado: (2019)

Comparison of Long-Term Use of Low Dose Rituximab and Mycophenolate Mofetil in Chinese Patients With Neuromyelitis Optica Spectrum Disorder
por: Lin, Jie, et al.
Publicado: (2022)

Phase I dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumors
por: Yao, James C, et al.
Publicado: (2017)

Radiation treatment planning with embedded dose escalation
por: Hrinivich, William T., et al.
Publicado: (2019)

The role of biological dose-escalation for pancreatic cancer
por: Bruynzeel, Anna M.E., et al.
Publicado: (2019)

Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma
por: Elganainy, Dalia, et al.
Publicado: (2018)

National trends in radiation dose escalation for glioblastoma
por: Wegner, Rodney E., et al.
Publicado: (2019)

Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis
por: Song, Yue, et al.
Publicado: (2023)

De-escalation of biological therapy in inflammatory bowel disease patients following prior dose escalation
por: Thomas, Pepijn W. A., et al.
Publicado: (2022)

Antimicrobial de-escalation in the critically ill patient and assessment of clinical cure: the DIANA study
por: De Bus, Liesbet, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_okg9tgg1059vl20v8r0g53tdgj